Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that its management will participate in a fireside chat at the Stifel Virtual Targeted Oncology Days on April 26, 2023, at 10:30 AM ET. The event aims to discuss the company's progress in developing innovative medicines for cancer treatment.

A live webcast will be accessible on the Company’s website under the “Investors” section, with an archived replay available for 90 days post-event. Deciphera's focus is on commercializing new treatments, notably QINLOCK®, a switch-control kinase inhibitor approved in multiple countries including the US, Canada, and the EU for the treatment of fourth-line GIST.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Stifel Virtual Targeted Oncology Days on Wednesday, April 26, 2023 at 10:30 AM ET.

A live webcast of the fireside chat will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New Zealand, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005065/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902



Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

What event is Deciphera Pharmaceuticals participating in on April 26, 2023?

Deciphera Pharmaceuticals will participate in the Stifel Virtual Targeted Oncology Days.

What time will Deciphera's fireside chat take place?

The fireside chat will take place at 10:30 AM ET.

How can I watch the Deciphera Pharmaceuticals fireside chat?

The fireside chat will be available as a live webcast on Deciphera's website.

How long will the replay of the Deciphera fireside chat be available?

The replay will be available for 90 days following the presentation.

What is QINLOCK® and where is it approved?

QINLOCK® is a switch-control kinase inhibitor for fourth-line GIST, approved in the US, Canada, the EU, and several other regions.